Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis
Silke Gillessen, Bertrand F. TOMBAL, Fabio Turco et al. · European Urology · 2025
Cited by 35 works. doi:10.1016/j.eururo.2024.11.027
Authors
- Silke Gillessen
- Bertrand F. TOMBAL
- Fabio Turco
- Ananya Choudhury
- Alejo Rodríguez‐Vida
- Enrique Gallardo
- Pedro Isaacsson Velho
- Franco Nolè
- Felipe Melo Cruz
- Yohann Loriot
- Ray McDermott
- Thierry Roumeguère
- Gedske Daugaard
- Emmanuelle Bompas
- Pablo Maroto
- Manuel Herrero Polo
- Karine Martins da Trindade
- Daniel D’Almeida Preto
- Iwona Skoneczna
References
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer
- Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors
- Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer
- Histopathological Assessment of Prostate Cancer Bone Osteoblastic Metastases
- The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer
- Practical guide to bone health in the spectrum of advanced prostate cancer.
- A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe
- EMA guidance on radium-223 dichloride in prostate cancer